chcuk@syneoshealth.com
  • Home
  • Contact
CHCUK
  • NIS
    • NIS Definitions
    • Study Classification
    • NIS Training Solutions
    • NIS Country-Specific Reports
    • NIS Regulatory Database
    • NIS Regulatory Consulting
    • NIS Resources & Useful Links
    • RWR Glossary
  • PCTs
    • PCT Definitions
    • PCT Regulatory Consulting
    • PCT Useful Links
    • RWR Glossary
  • GCP
    • GCP Definitions
    • GCP Useful Links
    • RWR Glossary
  • News
  • About
  • Contact
Select Page

GVP Module VIII – Revision 2 Published

10 Aug, 2016 | CHCUK News & Articles, GVP, News, NIS, Real Word Evidence

Guideline on good pharmacovigilance practices (GVP) Module VIII – emea_strap_url_cmyk_rev_en_std_cent.eps MASTERPost-authorisation safety studies (Rev 2)

Date for coming into effect of Revision 2 – 9 August 2016

Revision 2 contains the following:

  • Changes to VIII.A., clarifying the link between the legislation on non-interventional PASS and categories 1-3 of non-interventional PASS described in GVP Module V;
  • Changes to VIII.B., amending and re-organising the text of several sections to provide a better distinction between legal obligations and recommendations to marketing authorisation holders;
  • Changes to VIII.B.3.1, adding text in line with GVP Module VI Rev 1 to provide a recommendation on adverse events that will not be collected or reported;
  • Changes to VIII.B.3. and VIII.B.4 with the sentences referring to the notification of study information to the Agency (substantial amendments to PASS protocols, progress reports and final reports) moved to GVP Module VIII Addendum I Rev 2;
  • Change to VIII.B.4.3.2. (Format of study report) to add a section “Conclusion”;
  • Changes to VIII.B.8. (Impact on the risk management system) to only refer to GVP Module V;
  • Changes to previous VIII.C.1.d./now VIII.C.1.4., revising the text on joint studies to emphasise the role of the Agency and national competent authority to systematically encourage submission of joint protocols;
  • Updating of the structure to bring the Module in line with other GVP Modules as structuring has consolidated over time (previous B.1. and C.1. on scope moved to A and previous B.2. moved to A.1);Editorial amendments throughout the Module;
  • Revision of nearly all sections of VIII. Appendix 1 in order to:
    • provide updated and more detailed information on some study designs;
    • revise the terminology where needed
      • Change of the title;
      • Deletion of Tables XIII Add I.1. and XIII Add I.2. and simplification of presentation of submission requirements and recommendations based on legislation related to non-interventional post- authorisation safety studies;
      • Update of submission requirements for study protocols and progress reports according to Art 107m(5) based on updated information provided by Member States;
      • Addition of information regarding study registration in the EU PAS Register
[Read More…]

Categories

  • 21 Century Cures Act
  • 3D Printers
  • AI
  • Biological Products
  • Biosamples
  • Biosimilars
  • Brexit
  • CHCUK News & Articles
  • CHCUK NIS Database
  • Consultation
  • Cures Act
  • Cybersecurity
  • Data Integrity
  • Data Privacy
  • Digital Health Technology
  • EAP
  • eConsent
  • EFPIA
  • EHR
  • eletronic Signatures
  • EMA
  • EU Clinical Trials Regulation
  • FDA 1572
  • FDA Guidance
  • FDAMA114
  • GCP
  • GCP Inspections
  • GDPR
  • Genetic Research
  • GVP
  • HIPAA
  • HTA
  • Human Tissue Research
  • Immunological Products
  • Informed Consent
  • Market Access
  • Medical Apps
  • Medical Devices
  • News
  • NIS
  • NIS Considerations Report
  • Orphan Drugs
  • PASS
  • Patient Centricity
  • Pragmatic Trials
  • Professional Standards
  • Promotion and Advertising
  • PROs
  • Publication Guidelines
  • Rare Diseases
  • Real Word Evidence
  • Real World Evidence
  • Real World Research Design
  • Registry
  • Regulatory Grade RWE
  • Regulatory Intelligence
  • Regulatory Science
  • Reimbursement
  • RWD
  • Safety Management
  • Sunshine Regulations
  • Transparency
  • Uncategorized
  • Virtual Clinical Research
  • Webinar
  • White Paper

News

July 2022
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
« Feb    

Legal Information:

  • Terms & Conditions
  • Disclaimer
  • Privacy Notice

• CHCUK NIS Regulatory Database
• Contact CHCUK

  • Facebook
  • Twitter
Copyright © 2018 CHCUK. All Rights Reserved.

design by Poppy Design